“Four-Weekly Dosing Intervals With Subcutaneous Spesolimab Appear to Be Required for Optimal Prevention of Generalized Pustular Psoriasis Flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON Trials”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s492. https://doi.org/10.25251/skin.8.supp.492.